stoxline Quote Chart Rank Option Currency Glossary
  
MacroGenics, Inc. (MGNX)
17.94  0.75 (4.36%)    02-29 16:00
Open: 17.84
High: 18.6
Volume: 1,945,356
  
Pre. Close: 17.19
Low: 17.635
Market Cap: 1,113(M)
Technical analysis
2024-02-29 4:45:03 PM
Short term     
Mid term     
Targets 6-month :  22.01 1-year :  25.71
Resists First :  18.85 Second :  22.01
Pivot price 17.42
Supports First :  14.76 Second :  12.23
MAs MA(5) :  17.46 MA(20) :  17.17
MA(100) :  10.01 MA(250) :  7.4
MACD MACD :  1.1 Signal :  1.3
%K %D K(14,3) :  45.1 D(3) :  45.6
RSI RSI(14): 65.9
52-week High :  18.85 Low :  4.28
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MGNX ] has closed below upper band by 19.5%. Bollinger Bands are 36.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 18.62 - 18.71 18.71 - 18.79
Low: 17.43 - 17.53 17.53 - 17.61
Close: 17.79 - 17.95 17.95 - 18.08
Company Description

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Headline News

Thu, 29 Feb 2024
Is MacroGenics Inc (MGNX) Stock a Smart Investment Thursday? - InvestorsObserver

Thu, 29 Feb 2024
Analysts Estimate MacroGenics (MGNX) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Thu, 29 Feb 2024
MacroGenics (MGNX) to Release Quarterly Earnings on Thursday - AmericanBankingNEWS

Wed, 28 Feb 2024
MacroGenics, Inc. (NASDAQ:MGNX) Surges 27% Yet Its Low P/S Is No Reason For Excitement - Simply Wall St

Wed, 28 Feb 2024
Is MacroGenics Inc (MGNX) a Stock to Watch After Gaining 1.70% This Week? - InvestorsObserver

Tue, 27 Feb 2024
MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 62 (M)
Shares Float 52 (M)
Held by Insiders 2.7 (%)
Held by Institutions 100.6 (%)
Shares Short 8,340 (K)
Shares Short P.Month 7,730 (K)
Stock Financials
EPS 0.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.13
Profit Margin 41.1 %
Operating Margin -341.5 %
Return on Assets (ttm) -25 %
Return on Equity (ttm) 31.4 %
Qtrly Rev. Growth -75.1 %
Gross Profit (p.s.) 0
Sales Per Share 1.95
EBITDA (p.s.) -1.55
Qtrly Earnings Growth 0 %
Operating Cash Flow -21 (M)
Levered Free Cash Flow -48 (M)
Stock Valuations
PE Ratio 22.14
PEG Ratio -0.2
Price to Book value 5.73
Price to Sales 9.18
Price to Cash Flow -53.38
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android